Despite impressive clinical activity in B-cell lymphoma and melanoma, questions remain about the immunobiology of adoptive T-cell therapies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
June, C., Rosenberg, S., Sadelain, M. et al. T-cell therapy at the threshold. Nat Biotechnol 30, 611–614 (2012). https://doi.org/10.1038/nbt.2305
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2305
This article is cited by
-
Interleukin-armed chimeric antigen receptor-modified T cells for cancer immunotherapy
Gene Therapy (2018)
-
Next frontiers in CAR T-cell therapy
Molecular Therapy - Oncolytics (2016)
-
Engager T Cells: A New Class of Antigen-specific T Cells That Redirect Bystander T Cells
Molecular Therapy (2015)
-
CAR-T field booms as next-generation platforms attract big players
Nature Biotechnology (2015)
-
Building better monoclonal antibody-based therapeutics
Nature Reviews Cancer (2015)